Xtracef 200 Tablet DT contains Cefpodoxime Proxetil 200 mg, a third-generation oral cephalosporin antibiotic effective against a broad spectrum of bacterial infections. It is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, and uncomplicated gonorrhea caused by susceptible strains of bacteria. Cefpodoxime Proxetil acts by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. The tablet is designed as a dispersible formulation, facilitating ease of administration, particularly in patients with swallowing difficulties. Xtracef 200 Tablet DT demonstrates good oral bioavailability and achieves therapeutic concentrations in various body tissues and fluids. It is generally well tolerated; however, potential adverse effects include gastrointestinal disturbances such as diarrhea, nausea, and abdominal pain, as well as hypersensitivity reactions in patients with a history of beta-lactam allergy. Dosage and duration of therapy should be determined based on the type and severity of infection, as well as patient-specific factors including renal function. It is essential to complete the full prescribed course to prevent the development of resistance. Use during pregnancy and lactation should be under medical supervision. Xtracef 200 Tablet DT should be stored in a cool, dry place away from direct sunlight.